About Corium International (NASDAQ:CORI)
Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CORI
CUSIPN/A
Phone650-298-8255
Debt
Debt-to-Equity Ratio5.91%
Current Ratio1.40%
Quick Ratio1.34%
Price-To-Earnings
Trailing P/E Ratio-6.57
Forward P/E Ratio-7.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.86 million
Price / Sales12.21
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book23.93
Profitability
EPS (Most Recent Fiscal Year)($1.64)
Net Income$-47,790,000.00
Net Margins-148.07%
Return on Equity-403.15%
Return on Assets-62.88%
Miscellaneous
Employees213
Outstanding Shares36,120,000
Corium International (NASDAQ:CORI) Frequently Asked Questions
What is Corium International's stock symbol?
Corium International trades on the NASDAQ under the ticker symbol "CORI."
How were Corium International's earnings last quarter?
Corium International (NASDAQ:CORI) released its quarterly earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.06. The biopharmaceutical company earned $9.32 million during the quarter, compared to analysts' expectations of $7.48 million. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. View Corium International's Earnings History.
What price target have analysts set for CORI?
5 Wall Street analysts have issued 12 month price targets for Corium International's stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate Corium International's share price to reach $13.00 in the next year. View Analyst Ratings for Corium International.
What are Wall Street analysts saying about Corium International stock?
Here are some recent quotes from research analysts about Corium International stock:
- 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (4/16/2018)
- 2. Cantor Fitzgerald analysts commented, "Important update includes expectation to file donepezil patch NDA with pilot BE data. On 3/26, in conjunction with a presentation at an investor conference, CORI provided a corporate update (slide deck here). Likely of great interest to investors is the expectation that the NDA will be filed with data from the pilot bioequivalence (BE) study (see Exhibit 1 in this report)." (3/27/2018)
Are investors shorting Corium International?
Corium International saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,873,611 shares, an increase of 81.0% from the February 28th total of 1,587,260 shares. Based on an average daily trading volume, of 570,194 shares, the short-interest ratio is currently 5.0 days. Approximately 11.0% of the company's shares are short sold.
Who are some of Corium International's key competitors?
Some companies that are related to Corium International include OptiNose (OPTN), Adamas Pharmaceuticals (ADMS), NuCana (NCNA), GlycoMimetics (GLYC), Vanda Pharmaceuticals (VNDA), Karyopharm Therapeutics (KPTI), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), BeyondSpring (BYSI), Rocket Pharmaceuticals (RCKT), Omeros (OMER), AMAG Pharmaceuticals (AMAG), Endocyte (ECYT), Lannett (LCI), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA), Ziopharm Oncology (ZIOP) and Geron (GERN).
Who are Corium International's key executives?
Corium International's management team includes the folowing people:
- Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
- Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
- Dr. Joseph J. Sarret, Chief Bus. Officer (Age 51)
- Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
- Dr. Parminder Singh, CTO & VP of R&D (Age 54)
Has Corium International been receiving favorable news coverage?
News stories about CORI stock have been trending somewhat negative this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corium International earned a news sentiment score of -0.06 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.64 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Corium International's major shareholders?
Corium International's stock is owned by many different of institutional and retail investors. Top institutional investors include
RIDGEBACK CAPITAL INVESTMENTS L.P.
(5.20%). Company insiders that own Corium International stock include David Greenwood, Eric Bjerkholt, Healthcare Master Fun Broadfin, Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Perceptive Advisors Llc and Timothy D Sweemer. View Institutional Ownership Trends for Corium International.
How do I buy shares of Corium International?
Shares of CORI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corium International's stock price today?
One share of CORI stock can currently be purchased for approximately $10.77.
How big of a company is Corium International?
Corium International has a market capitalization of $389.06 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Corium International employs 213 workers across the globe.
How can I contact Corium International?
Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]
MarketBeat Community Rating for Corium International (CORI)
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corium International (NASDAQ:CORI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Corium International in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 20.71%. The high price target for CORI is $14.00 and the low price target for CORI is $10.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.00 | $13.00 | $13.00 | $13.1429 |
| Price Target Upside: | 20.71% upside | 8.70% upside | 30.65% upside | 21.13% upside |
Corium International (NASDAQ:CORI) Consensus Price Target History
Corium International (NASDAQ:CORI) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Corium International (NASDAQ:CORI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Corium International (NASDAQ CORI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 30.80%
Institutional Ownership Percentage: 88.58%
Corium International (NASDAQ CORI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/18/2018 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 510,000 | $12.54 | $6,395,400.00 | |  |
| 1/16/2018 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,350 | $11.83 | $595,640.50 | | |
| 11/17/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 500,000 | $10.96 | $5,480,000.00 | | |
| 11/2/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 150,000 | $11.05 | $1,657,500.00 | | |
| 10/4/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 218,100 | $11.01 | $2,401,281.00 | | |
| 8/22/2017 | Parminder Singh | Insider | Sell | 30,415 | $7.59 | $230,849.85 | 30,762 | |
| 8/17/2017 | Parminder Singh | Insider | Sell | 32,000 | $7.61 | $243,520.00 | | |
| 8/17/2017 | Timothy D. Sweemer | CAO | Sell | 12,012 | $7.62 | $91,531.44 | | |
| 8/16/2017 | Timothy D. Sweemer | CAO | Sell | 15,488 | $7.82 | $121,116.16 | | |
| 7/20/2017 | Joseph J. Sarret | Insider | Sell | 2,038 | $8.95 | $18,240.10 | | |
| 6/30/2017 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 301,004 | $7.71 | $2,320,740.84 | | |
| 5/25/2017 | Perceptive Advisors Llc | Major Shareholder | Buy | 1,902,400 | $6.25 | $11,890,000.00 | | |
| 5/19/2016 | Eric Bjerkholt | Director | Buy | 24,500 | $3.64 | $89,180.00 | | |
| 5/12/2016 | David Greenwood | Director | Buy | 3,000 | $3.58 | $10,740.00 | 3,000 | |
| 2/25/2015 | Peter D Staple | CEO | Buy | 3,600 | $6.99 | $25,164.00 | | |
| 11/24/2014 | Robert S Breuil | CFO | Buy | 4,600 | $5.38 | $24,748.00 | | |
| 11/21/2014 | Peter D Staple | CEO | Buy | 9,000 | $5.34 | $48,060.00 | | |
| 8/27/2014 | Peter D Staple | CEO | Buy | 2,578 | $6.10 | $15,725.80 | | |
| 5/30/2014 | Peter D Staple | CEO | Buy | 7,200 | $7.04 | $50,688.00 | | |
| 4/8/2014 | Woodlands Health Venture Essex | Major Shareholder | Buy | 400,000 | $8.00 | $3,200,000.00 | | |
(Data available from 1/1/2013 forward)
Corium International (NASDAQ CORI) News Headlines
| Source: |
|
Corium International (NASDAQ:CORI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Corium International (NASDAQ:CORI) Income Statement, Balance Sheet and Cash Flow Statement
Corium International (NASDAQ CORI) Stock Chart for Monday, April, 23, 2018
Loading chart…
